NovaBay Pharmaceuticals, Inc.
NBY
$1.44
-$0.09-5.88%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 521.00K | -- | -- | 2.31M | 2.42M |
| Total Other Revenue | -- | -- | -- | -3.00K | 17.00K |
| Total Revenue | 521.00K | -- | -- | 2.31M | 2.44M |
| Cost of Revenue | 479.00K | -- | -- | 807.00K | -- |
| Gross Profit | 42.00K | -- | -- | 1.50M | -- |
| SG&A Expenses | 1.21M | 1.89M | 2.70M | 2.78M | 1.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.69M | 1.89M | 2.70M | 3.60M | 1.70M |
| Operating Income | -1.17M | -1.89M | -2.70M | -1.29M | -1.70M |
| Income Before Tax | -1.33M | -1.96M | -3.33M | -1.32M | -1.85M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.33M | -1.96M | -3.33M | -1.32M | -1.85M |
| Earnings from Discontinued Operations | 40.00K | 42.00K | 11.00M | 111.00K | 642.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.29M | -1.92M | 7.67M | -1.21M | -1.21M |
| EBIT | -1.17M | -1.89M | -2.70M | -1.29M | -1.70M |
| EBITDA | -1.17M | -1.89M | -2.70M | -1.28M | -1.70M |
| EPS Basic | -1.10 | -1.65 | 7.22 | -0.76 | -9.60 |
| Normalized Basic EPS | -0.66 | -1.05 | -1.61 | -0.52 | -4.98 |
| EPS Diluted | -1.12 | -1.66 | 7.22 | -0.76 | -9.62 |
| Normalized Diluted EPS | -0.66 | -1.05 | -1.58 | -0.52 | -4.98 |
| Average Basic Shares Outstanding | 1.18M | 1.16M | 1.06M | 1.60M | 231.00K |
| Average Diluted Shares Outstanding | 1.18M | 1.16M | 1.08M | 1.60M | 231.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -372.39% | -- | -- | -- | -- |